Nanomedical Diagnostics Launches New Graphene Biosensor for Label-free Characterization of Antibodies, Peptides, and Small Molecule Compounds

Share Article

NH2 Agile biosensors provide flexible kinetic characterization for drug discovery research.

Agile R100 graphene biosensor for kinetic characterization

The new NH2 Agile Biosensor

Users now have a variety of linkage options to test what surface chemistry provides the strongest responses and reliable results.

Nanomedical Diagnostics, leading manufacturer of graphene biosensors that accelerate pharmaceutical and biotherapeutics development, launches the new Carboxyl-Immobilization Biosensor – NH2, for use with the company’s Agile R100 label-free personal assay system. The new biosensor allows for immobilization of targets onto the sensor surface via carboxyl groups and compliments the existing COOH Agile biosensor which enables immobilization via amine groups.

“Our goal is to provide our customers with the flexibility needed to develop assays quickly and efficiently to fully understand their biomolecular interactions,” says Nanomedical Diagnostics CEO, Ross Bundy. “With the new NH2 Agile biosensor, researchers now have a variety of linkage options to use the the surface chemistry that provides the strongest response and reliable results.”

The new NH2 biosensor enables easier, faster assay optimization for researching unknown drug interactions that are not well-characterized with an additional way to manipulate target orientation and test for strong signals. Like all Agile biosensors, the NH2 sensor is regeneration-capable and highly cost-effective, providing up to 10 measurements with just a 10 µL drop of sample. Combined with the kinetic characterization platform Agile R100, researchers now have an accessible way to measure biomolecular interactions in real-time. The easy-to-use, single sample format provides reliable label-free data to validate hits accurately and accelerate the drug discovery process.

“The NH2 biosensor is the second chemistry released by the company in two months,” continues Mr. Bundy. “One of our top priorities is to expand the Agile R100 system menu quickly to meet the pressing need in drug discovery for an orthogonal kinetic characterization platform to verify data. Agile R100 is based on a breakthrough electrical technique called Field Effect Biosensing that enables affordable kinetics without compromising sensitivity and reliability.”

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive label-free kinetic characterization of biomolecular interactions for accelerated drug discovery. As the world’s leading developer and manufacturer of next-generation graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Visit website